UNION therapeutics announces presentation of new data on orismilast at the EADV Congress 2023
· Late-breaking presentation of data from the OSIRIS IIT PoC study of oral orismilast in hidradenitis suppurativa (HS) at the European Academy of Dermatology and Venerology Congress 2023 · Additional e-posters on the efficacy and safety of orismilast in moderate-to-severe psoriasis from the IASOS Phase 2b study and biomarker analyses from the skin of patients in the IASOS study, will be presented · Positive topline data from the IASOS study was reported early January 2023 and for the OSIRIS study in June 2023 · Orismilast is a next generation high-potency PDE4B/D selective